Across TCGA pan-cancer cohorts, SSX7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SSX7 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher SSX7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SSX7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SARC, UCEC, and LIHC are the cancer types where SSX7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.181	0.638	.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.031	10	view →
LIHC	DFS	Median	All	0.112	0.544	.007	6	view →
SKCM	DFS	Median	All	0.813	0.609	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SSX7 tumor-vs-normal RNA expression · all SSX7 data types